[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National University of Ireland, Galway, Ireland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":158},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,66,95,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100563783","heart-failure-virtual-ward-research-study-100563783",false,"NCT06620653","Heart Failure Virtual Ward Research Study","HF-VW","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with a recent hospitalisation.\n* Known ejection fraction and NYHA Class\n* Known or de novo Heart Failure\n* Patient or carer able to speak and understand English\u002FIrish\n* Willing to participate in the study.\n* Within catchment area of the Saolta group.\n\nExclusion Criteria:\n\n* Patients who decline to participate in the study.\n* Patient in palliative care or with a life expectancy of less than one year.\n* Patients referred to skilled nursing facilities or nursing homes at hospital discharge.\n* Patients with planned intervention on the mitral or aortic valve during admission or scheduled early after discharge.\n* Planned haemodialysis.\n* Patients included in other randomized controlled trials.\n* Patients who, at the investigator's discretion, are considered unable to participate in the study, mainly due to a previous history of non- compliance with medication and follow-up appointments, language barrier, or moderate or severe cognitive impairment without the support of a family member\u002Fcaregiver.\n* Patients with asymptomatic (NYHA class I) left ventricular dysfunction, usually in the setting of an acute myocardial infarction.\n* The lack of information technology (IT) literacy will not be an exclusion criterion.","ALL","18 Years",{"count":19,"type":20},346,"ESTIMATED","INTERVENTIONAL",[23],"NA","The main aim will be to evaluate whether a follow-up with virtual wards reduces HF hospitalisation at three months follow-up. Hospital admission will be defined as any hospital admission, or an emergency room stay of more than 24 h requiring IV diuretics.\n\nThe secondary objectives will be to evaluate whether this intervention reduces all-cause mortality, all-cause hospitalisation at three months, is cost-effectiveness, is associated with a higher percentage of prescription and dose of prognostic medication and improves the quality of life. To assess the potential long-term effects of the virtual wards follow-up, we will evaluate whether this intervention reduces all-cause mortality and HF hospitalisation at 6- and 12-months by a telephone call\u002Fvirtual outpatients' appointment.\n\nThe study outcomes will be ascertained at each visit. Given the study design, it is impossible to assess the endpoints in a blinded manner. Clinical events during the study will be adjudicated by an operational committee whose members will be unaware of the group assignment.",[26],"Heart Failure","RECRUITING","2026-04-10",{"date":30,"type":31},"2026-04-15","ACTUAL",{"date":33,"type":31},"2024-10-18",{"date":35,"type":20},"2027-05",{"name":37,"class":38},"National University of Ireland, Galway, Ireland","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100633277","self-expanding-hydra-transcatheter-heart-valve-thv-series-versus-balloon-expandable-devices-for-valve-in-valve-transcatheter-aortic-valve-implantation-tavi-for-patients-with-failed-surgical-aortic-bioprosthesis-100633277","NCT07524595","Self-Expanding Hydra Transcatheter Heart Valve (THV) Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis.","Randomised Comparison of Self-Expanding Hydra THV Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis: REVIVAL Trial","REVIVAL","\"Inclusion Criteria\":\n\n1. Male or Female patient ≥18 years of age\n2. Severe hemodynamic valve deterioration of a surgically implanted bioprosthetic aortic valve, including severe valve stenosis and\u002For severe valve regurgitation, as determined by the Heart Team assessment\n3. Patients eligible for transfemoral TAVI with both study THV platforms per heart team consensus.\n4. TAVI (with or without fracture of surgical valve) is suitable with commercially available sizes of both Hydra and Sapien\u002FMyvall BEVs.\n5. Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethics Committee and is willing to comply with all protocol-required (follow-up) evaluations.\n\n\"Exclusion criteria\":\n\n1. Patients unwilling to provide an informed consent, or whose legal representative object to their participation in the study\n2. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in woman of child-bearing potential according to local practice)\n3. Patients with non-transfemoral TAVI access.\n4. Surgical or transcatheter valve in mitral position (mitral rings are not an exclusion)\n5. Patients who had received the Bentall procedure.\n6. Patients with active bacterial endocarditis or ongoing sepsis ≤6 months prior to the index procedure\n7. Echocardiographic evidence of intracardiac mass, thrombus or vegetation\n8. Acute myocardial infarction ≤30 days before the intended TAVI procedure\n9. Known hypersensitivity or contraindication to antithrombotic therapy (or inability to be anticoagulated during the procedure), nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated\n10. Patients with severe left ventricular dysfunction and ejection fraction \\\u003C30% or hemodynamic instability requiring inotropic agent or mechanical support.\n11. Patients with significant renal insufficiency (serum creatinine \\>3.0 mg\u002FdL (265.5μmol\u002FL)) and\u002For end stage renal disease requiring chronic dialysis\n12. Patients who are at very high risk of coronary obstruction (e.g., VIVID classification IIB, IIIB, IIIC) and are judged by the heart team to require upfront leaflet laceration (e.g. Basilica or Unicorn procedure) or chimney or snorkel stenting as part of the TAVI procedure.\n13. Any planned surgical or peripheral procedure to be performed in next 30-day after the index procedure\n14. Life expectancy \\\u003C12 months due to non-cardiac co-morbid conditions including carcinomas, chronic liver disease, chronic renal disease or chronic end-stage pulmonary disease",{"count":49,"type":20},111,[23],"This is a prospective, randomised, international, multicentre, open-label, investigator-initiated study in patients undergoing valve-in-valve Transcatheter Aortic Valve Implantation (TAVI) for failed surgical aortic bioprosthesis. A total of 111 patients will be randomized in a 2:1 ratio, with 74 patients assigned to self-expanding Hydra THV Series and 37 patients assigned to BEV (Sapien THV Series and MyVal THV Series).",[53,54,55,56],"AORTIC VALVE DISEASES","Valve-in-valve Procedures","Surgical Valve Replacement","Valve Disease, Aortic","NOT_YET_RECRUITING","2026-04-05",{"date":60,"type":31},"2026-04-13",{"date":62,"type":20},"2026-04",{"date":64,"type":20},"2027-08",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100629689","a-single-arm-interventional-trial-of-pepper--robot-delivered-cancer-education-for-adults-with-intellectual-disability-100629689","NCT07477938","A Single-Arm Interventional Trial of Pepper- Robot Delivered Cancer Education for Adults With Intellectual Disability","Pilot Single Arm Clinical Trial of Pepper, a Semi Humanoid Robot -Delivered Cancer Awareness and Education Intervention for Adults With Intellectual Disability","Pep-SMARTID","Inclusion Criteria:\n\n1. Adults (≥18 years) with an intellectual disability requiring any level of support needs.\n2. Able to provide informed consent, or where capacity is limited, able to assent with decision support in line\n3. Attending the disability service day center.\n4. Sufficient receptive\u002Fexpressive communication (with supports) to participate in interactive sessions\n\nExclusion Criteria:\n\n1 Severe sensory impairments that cannot be reasonably accommodated (e.g., profound hearing\u002Fvision loss without assistive solutions available for the session).",{"count":75,"type":20},25,[23],"Individuals with Intellectual disability face numerous barriers to cancer education, awareness and screening, including communication challenges, anxiety, and a lack of accessible educational resources. Traditional methods often fail to meet their unique learning needs, contributing to lower screening rates , delayed diagnoses and poorer outcomes..\n\nSocially assistive robots, have demonstrated effectiveness in delivering interactive, engaging, and tailored education, helping individuals with cognitive impairments better understand medical procedures and the importance of preventive care.\n\nThe study investigators propose to conduct a pilot single arm clinical trial with a semi humanoid robot to deliver cancer awareness education to adults with intellectual disability attending a disability day service in Ireland .The semi humanoid robot will be programmed to engage in 2 way communication about the cancer related educational content that is uploaded on its system.\n\n.Approximately 25 adults with ID will receive the robot led educational intervention addressing both breast and colorectal cancer awareness and screening. This a pragmatic pilot study to inform a future larger controlled clinical trial Our overall objective is to Improve breast and colorectal cancer awareness knowledge level among adults with ID receiving a robot-delivered education intervention",[79,80,81],"Cancer Awareness and Prevention Education","Breast Cancer Awareness","Intellectual Disabilities (F70-F79)",[83,84,85,86],"cancer awareness and prevention education","intellectual disablity","robotics","breast self examination","2026-03-13",{"date":89,"type":31},"2026-03-17",{"date":91,"type":20},"2026-05-01",{"date":93,"type":20},"2026-09-30",{"name":37,"class":38},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100433366","the-pioneer-iv-study-is-comparing-clinical-outcomes-between-angiography-derived-physiology-guidance-to-usual-care-in-an-all-comers-pci-population-with-unrestrictive-use-of-the-ht-supreme-sirolimus-eluting-stent-100433366","NCT04923191","The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent","Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated With Unrestricted Use of the Healing-Targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy After 1-month of Dual-antiplatelet Therapy","PIONEER-IV","Inclusion Criteria:\n\n* Patient has chronic stable angina, acute coronary syndromes or silent ischemia;\n* Presence of one or more coronary artery stenoses of ≥50% (by visual assessment) in a native coronary artery (with or without prior stent\u002Fother device treatment) or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation;\n* The vessel should have a reference vessel diameter of at least 2.25 mm by visual assessment (no limitation on the number of treated lesions, vessels, or lesion length);\n* Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee and is willing to comply with all protocol-required (follow-up) evaluations.\n\nExclusion Criteria:\n\n1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice);\n2. Known intolerance to cobalt chromium, and medications such as sirolimus, aspirin, heparin, bivalirudin or P2Y12 inhibitors;\n3. Planned major elective surgery requiring discontinuation of (dual)anti platelet therapy (DAPT) within 12 months of procedure;\n4. Concurrent medical condition with a life expectancy of less than 3 years;\n5. Currently participating in another trial and not yet at its primary endpoint;\n6. Active pathological bleeding;\n7. History of intracranial haemorrhage.",{"count":104,"type":20},2540,[23],"PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient population (including patients with high bleeding risk, HBR) undergoing PCI with unrestrictive use of the HT Supreme sirolimus-eluting stent. Patients will be randomized to either angio-based physiology guidance angio-FFR (Quantitative Flow Ratio and coronary angiography-derived FFR, caFFR) or local routine diagnostic procedure (LRDP) and usual care. Patients will be treated with 1-year P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy in approximately 2540 (2\\*1270) patients. All patients (both cohorts) must receive dual anti-platelet therapy, being aspirin (ASA) and ticagrelor for 1 month, followed by 11 months of ticagrelor only (i.e. monotherapy). At 1 year, ticagrelor monotherapy is replaced by aspirin monotherapy or left to the discretion of the operator.",[108],"Coronary Artery Disease",[110,111,112,113,114,115,116,117],"coronary artery disease","ischemia","quantitative flow ratio (QFR)","P2Y12 monotherapy","drug-eluting stent","physiology guidance","angio-FFR","Coronary Angiography-derived FFR (caFFR)","2023-10-26",{"date":120,"type":31},"2023-10-30",{"date":122,"type":31},"2021-11-12",{"date":124,"type":20},"2029-01",{"name":37,"class":38},19,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100510041","understanding-cardiac-events-in-breast-cancer-100510041","NCT05921279","Understanding CARdiac Events in Breast Cancer","Understanding CARdiac Events in Breast Cancer - Pilot Cardio-Oncology Assessment and Surveillance Pathway for Breast Cancer Patients","UCARE","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n* Ability to read and understand English\n* Breast Cancer Stage I- III planned to receive systemic chemotherapy\n\nExclusion Criteria:\n\n* Patients not for systemic chemotherapy with curative intent\n* Patients who are unable to co-operate with the study protocol\n* Patients who are unable to give informed consent","FEMALE","90 Years",{"count":138,"type":20},100,"OBSERVATIONAL","In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts.\n\nThis research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease.",[142,143,144,145,26,146],"Breast Cancer","Cardiotoxicity","Cardiomyopathies","Chemotherapeutic Toxicity","Oncology",[148],"Cardio oncology","2023-07-24",{"date":151,"type":31},"2023-07-25",{"date":153,"type":31},"2023-01-14",{"date":155,"type":20},"2026-07",{"name":37,"class":38},4,""]